Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group

J. Fernando Arevalo, Andres F. Lasave, Lihteh Wu, Dhariana Acon, Michel E. Farah, Roberto Gallego-Pinazo, Arturo A. Alezzandrini, Veronica Fortuna, Hugo Quiroz-Mercado, Guillermo Salcedo-Villanueva, Mauricio Maia, Martin Serrano, Sergio Rojas

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25mg IVB and had a minimum follow-up of 60months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60months. Mean CMT decreased from 403.5±142.2μm at baseline to 313.7±117.7μm over 5years follow-up (p≤0.0001). Conclusions The early visual gains due to IVB were not maintained 5years after treatment.

Original languageEnglish (US)
Pages (from-to)1605-1610
Number of pages6
JournalBritish Journal of Ophthalmology
Issue number12
StatePublished - Dec 2016


  • Macula
  • Neovascularisation
  • Posterior Chamber
  • Retina
  • Treatment Medical

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group'. Together they form a unique fingerprint.

Cite this